This study investigated the prevalence of early signs of cardiovascular damage in patients with HCV cirrhosis. Is such damage reversible following treatment with DAAs?
Alimentary Pharmacology & Therapeutics
Original Article: Cardiovascular Damage in Patients With HCV Cirrhosis